You are here

Dec 19, 2016

Iproteos, in collaboration with the group of Prof. Javier Meana, from the University of Basque Country and CIBERSAM, and Prof. Giralt, from IRB Barcelona, has just published an article at European Neuropsychopharmacology. The paper, entitled "The prolyl oligopeptidase inhibitor IPR19 ameliorates cognitive deficits in mouse models of schizophrenia", describes the efficacy of a novel procognitive drug for the treatment of Cognitive Impairment Associated to Schizophrenia (CIAS).

Oct 25, 2016

Iproteos has closed a funding round of 1.5M €, led by Caixa Capital Risc and with participation of Kinled Holding, a Hong Kong based investment company with offices in London, New York and Zurich, and the biotech Ascil Biopharm.

Aug 30, 2016

The city of Barcelona will host the 27th CPhI Worldwide. The event, that will take place on 4th-6th October 2016, is an excellent scenario for networking in the pharma business. More than 36,000 professionals will attend CPhI Worldwide, fact that contributes to make this event one of the most important shows for pharma industry and a must attend event. The key pharma sectors are represented, including ingredients, APIs, excipients, finished dosage and contract services among others.

Aug 03, 2016

Iproteos will attend next BIO Spain that will be held from the 28th to the 30th of September in Bilbao. Teresa and Laura will participate in the partnering event, promoting the science that is being carried out at Iproteos. Specifically, one of the objectives of Iproteos is to build partnerships around IPROTech, a platform for the discovery of innovative drug candidates.

May 27, 2016
On Tuesday 14th of June 2016, Iproteos will celebrate an Ordinary and Extraordinary General Meeting. More information is given in the link below. El martes 14 de Junio de 2016, Iproteos celebrará una Junta General Ordinaria y Extraordinaria. Se puede encontrar toda la información necesaria en el siguiente enlace: CONVOCATORIA JUNTA GENERAL IPROTEOS 14 DE JUNIO 2016
May 09, 2016

Iproteos has launched its second equity crowdfunding campaign to raise 250,000 euros through the Capital Cell platform in order to complete the preclinical regulatory phase with their compound IPR19, one of the few drugs being developed around the world to stop and reverse the cognitive deficits of schizophrenia (CIAS). The first round, launched in June 2014, was the first in the Spanish biotechnology sector.